Hepatotoxicity with combination of vemurafenib and ipilimumab
about
The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibOff-label use of targeted therapies in oncologyClinical utility of nivolumab in the treatment of advanced melanomaCancer immunotherapy: the beginning of the end of cancer?Updates in Therapy for Advanced MelanomaMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaImportance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodiesNew strategies in immunotherapy for non-small cell lung cancerLong-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsTailoring the Treatment of Melanoma: Implications for Personalized MedicineImmune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyThe importance of animal models in tumor immunity and immunotherapyUniverses collide: combining immunotherapy with targeted therapy for cancerThe GIST of targeted therapy for malignant melanomaImmune Checkpoint Blockade in Cancer TherapyPathways and therapeutic targets in melanomaTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsNew treatments for metastatic melanomaToxicities of Immunotherapy for the PractitionerThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyApproaches to modernize the combination drug development paradigmStrategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaNivolumab in melanoma: latest evidence and clinical potentialIpilimumab: from preclinical development to future clinical perspectives in melanoma.The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseSequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Melanoma: more answers, more questionsInactivation of MYC reverses tumorigenesis.T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor RegressionNew developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapyBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerResponse to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner
P2860
Q26744335-98F01029-C73D-4451-BF3B-E0C82722033AQ26747685-45EF0EAC-EF0D-4457-99DB-BC34AFE7850FQ26751268-0E3D3961-95EC-4D49-8C89-ECDFF391B737Q26752277-27EF51EC-AC0C-41BD-8953-520C80592DA3Q26771119-0B1B61E1-5ED5-4AEC-9A30-5D70ED01A888Q26771192-8A56790A-C098-429E-88E7-9058317B4CBBQ26772015-9082CD9A-F13E-4947-AE7D-C60F28CE9017Q26775034-CC3CD7A6-CB45-43AF-9119-A28B3AD0D981Q26775385-85578623-DEE2-4F97-A5CA-73681D16E77CQ26775546-7740E5A1-640E-44C2-A226-1906D1E9C59FQ26775806-6BCE4222-FF4E-4B41-B528-CB80BB0B73B3Q26796309-6CA8B46A-4392-4399-A6C6-8B1C7203B033Q26823861-8C1AA870-1817-4829-83A4-54AE6D8BAFFEQ26825316-60F25185-79DF-4C28-A071-A003002B6269Q26827092-972CE280-1E18-4CFF-8EAF-D725875AFD08Q26830509-97103DF3-9A94-4324-87E9-12100A68ABF8Q26865736-EB65FF85-5292-478E-8B50-7D93AB42BA72Q26996518-AAEFD16F-6087-471B-B10F-4BE7983540BAQ27007068-F42CAAE0-57FA-405F-BF2E-F3BE5A4FFF33Q27008140-5707AF8D-194E-4BD6-B9AC-A03478D7A933Q27022789-5A6A9DD1-0E36-4F45-8498-0ED5F0541E9EQ27691824-596D0B56-A37A-437A-B264-0F402EED3684Q28066199-412A3B80-08A1-4998-B555-B0627476A64EQ28072074-C0029C87-8C7F-4797-BB9D-03F21EF60175Q28077815-4A35567E-14B6-47B0-AB7B-340F376FCC79Q28088496-1961C0A6-D5A6-495D-BC36-D43F8C0E412CQ28258598-87827A7D-1AE0-4488-8336-E1703515C6E5Q30240751-A6500378-9D07-46FB-835E-F7965F3BB928Q30384301-A88AF444-C0B3-48B1-B5F6-B26CCBE124DCQ30746423-5576A181-FB37-49D1-82A6-E93724F8A63AQ30916013-5FBC175D-114B-48BF-8FCE-E2492DF00477Q31043365-1AAE4AF8-66FF-426E-88DC-95054DD4C43CQ33591876-A184BB00-AB86-4F59-BD50-991A2CA69930Q33777422-41AAECAD-5E21-492C-972D-354584FF130AQ33784668-B61B9E25-9484-44C8-97DF-77F9B4458F5DQ33816848-8F509EB9-F6D2-48FF-91F3-0C6716A15811Q33824552-44CBA5E9-66B2-492A-9154-638BD6D12EFDQ33862861-29AE345B-5C5D-44D6-9139-CA4C75100874Q33898182-44F266C9-5070-4255-93A1-C03B255479E6Q33902560-FBEA0BEF-4D75-43CF-B038-EFCEB2F7F4CC
P2860
Hepatotoxicity with combination of vemurafenib and ipilimumab
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Hepatotoxicity with combination of vemurafenib and ipilimumab
@ast
Hepatotoxicity with combination of vemurafenib and ipilimumab
@en
Hepatotoxicity with combination of vemurafenib and ipilimumab
@nl
type
label
Hepatotoxicity with combination of vemurafenib and ipilimumab
@ast
Hepatotoxicity with combination of vemurafenib and ipilimumab
@en
Hepatotoxicity with combination of vemurafenib and ipilimumab
@nl
prefLabel
Hepatotoxicity with combination of vemurafenib and ipilimumab
@ast
Hepatotoxicity with combination of vemurafenib and ipilimumab
@en
Hepatotoxicity with combination of vemurafenib and ipilimumab
@nl
P2093
P3181
P356
P1476
Hepatotoxicity with combination of vemurafenib and ipilimumab
@en
P2093
Cyril Konto
F Stephen Hodi
Jedd Wolchok
Margaret Callahan
P304
P3181
P356
10.1056/NEJMC1302338
P407
P50
P577
2013-04-04T00:00:00Z